IRC-083927 is a new tubulin binder that inhibits growth of human tumor cells resistant to standard tubulin-binding agents

Molecular Cancer Therapeutics
Anne-Marie LiberatoreGregoire Prevost

Abstract

Tubulin is a validated target for antitumor drugs. However, the effectiveness of these microtubule-interacting agents is limited by the fact that they are substrates for drug efflux pumps (P-glycoprotein) and/or by the acquisition of point mutations in tubulin residues important for drug-tubulin binding. To bypass these resistance systems, we have identified and characterized a novel synthetic imidazole derivative IRC-083927, which inhibits the tubulin polymerization by a binding to the colchicine site. IRC-083927 inhibits in vitro cell growth of human cancer cell lines in the low nanomolar range. More interesting, it remains highly active against cell lines resistant to microtubule-interacting agents (taxanes, Vinca alkaloids, or epothilones). Such resistances are due to the presence of efflux pumps (NCI-H69/LX4 resistant to navelbine and paclitaxel) and/or the presence of mutations on beta-tubulin and on alpha-tubulin and beta-tubulin (A549.EpoB40/A549.EpoB480 resistant to epothilone B or paclitaxel). IRC-083927 displayed cell cycle arrest in G(2)-M phase in tumor cells, including in the drug-resistant cells. In addition, IRC-083927 inhibited endothelial cell proliferation in vitro and vessel formation in the low nanomolar ra...Continue Reading

References

Mar 1, 1973·Proceedings of the National Academy of Sciences of the United States of America·M L ShelanskiC R Cantor
Jun 11, 1996·International Journal of Cancer. Journal International Du Cancer·G GiacconeH M Pinedo
Mar 1, 1996·Medicinal Research Reviews·E Hamel
Mar 10, 1998·Anti-cancer Drugs·A SparreboomJ H Beijnen
Jul 17, 1998·Medicinal Research Reviews·A JordanA T McGown
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M MonzóC Martín
Mar 15, 2001·Critical Reviews in Oncology/hematology·H Choy
Oct 30, 2001·Critical Reviews in Oncology/hematology·A Kruczynski, B T Hill
Jun 13, 2002·International Journal of Experimental Pathology·Gillian M TozerSally A Hill
Apr 23, 2003·Experimental Cell Research·Ralph W KunclRobert Adams
Mar 3, 2004·International Journal of Cancer. Journal International Du Cancer·Simon P NewmanMichael J Reed
Mar 9, 2004·The Lancet Oncology·Helen K BerriemanLynn Cawkwell
Mar 12, 2004·Anti-cancer Drugs·Catharine M L West, Pat Price
May 6, 2004·Cancer Research·Marie-Christine BrezakBernard Ducommun
Aug 28, 2004·Expert Opinion on Investigational Drugs·Scott L Young, David J Chaplin
Dec 8, 2004·Mini Reviews in Medicinal Chemistry·Mohd N Islam, Magdy N Iskander
Feb 22, 2005·Current Medicinal Chemistry. Anti-cancer Agents·Jun Zhou, Paraskevi Giannakakou
Jun 16, 2005·Molecular Cancer Therapeutics·Chia-Ping Huang YangSusan Band Horwitz
Mar 21, 2006·Pathologie-biologie·Gerhardt AttardJohann De Bono
May 6, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Kenneth R HandeMace L Rothenberg
Mar 28, 2007·Drugs·Matti S AaproVéronique Trillet-Lenoir
Oct 17, 2007·Molecular Cancer Therapeutics·Shanghua YinSudha Veeraraghavan
Dec 22, 2007·Expert Opinion on Investigational Drugs·Mark J McKeage
Jan 29, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Simon P NewmanAtul Purohit

❮ Previous
Next ❯

Citations

May 30, 2009·Cancer Chemotherapy and Pharmacology·Seema-Maria NathwaniDaniela M Zisterer
Jul 21, 2012·Pharmaceutical Research·Yan LuDuane D Miller
Feb 10, 2010·Expert Opinion on Investigational Drugs·Si-Meng ChenJian Ding
Nov 28, 2012·Critical Reviews in Oncology/hematology·Céline ClémensonEric Deutsch
Sep 7, 2011·Analytical Biochemistry·Karen C Morrison, Paul J Hergenrother
Dec 17, 2009·Journal of Biomolecular Screening·Nick Thomas
Feb 23, 2010·Journal of Medicinal Chemistry·Wen-Tai LiChiung-Tong Chen

❮ Previous
Next ❯

Related Concepts

Related Feeds

Angiogenesis Inhibitors to Treat Cancer

Cancer treatments including angiogenesis inhibitors prevent tumor cells from receiving nutrients and oxygen. Here is the latest research on angiogenesis inhibitors for the treatment of cancer.